Sun Ophthalmics

Sun Ophthalmics is the branded ophthalmic division of Sun Pharmaceutical Industries, specializing in the development and commercialization of innovative eye care products for the U.S. market. The company's portfolio features several FDA-approved treatments, including CEQUA (cyclosporine) for dry eye disease, BromSite (bromfenac) for post-operative inflammation, and Xelpros (latanoprost) for glaucoma. Sun Ophthalmics utilizes advanced drug delivery technologies, such as the DuraSite platform and nanomicellar NCELL technology, to enhance the efficacy and bioavailability of its therapies. Established in 2015, the division has rapidly expanded through strategic acquisitions of companies like InSite Vision and Ocular Technologies. With a dedicated team of eye care professionals and a robust pipeline of specialty pharmaceuticals, Sun Ophthalmics is committed to improving patient outcomes in chronic and acute ocular conditions.